2018 American Transplant Congress
Val-Ganciclovir Prophylaxis Delays Onset of EBV Viremia in the First Year Post-Solid Organ Transplantation in High-Risk Patients
1University of British Columbia, Vancouver, Canada; 2University of Manitoba, Winnipeg, Canada.
Introduction: Donor-derived primary Epstein-Barr virus (EBV) infection poses serious risks to EBV naïve children post-solid organ transplantation, including development of EBV-related PTLD. Currently, there is…2018 American Transplant Congress
A Retrospective Review of De Novo Coccidioidomycosis among Remote Solid Organ Transplant Recipients in Arizona
Background: Solid organ transplant (SOT) recipients residing in a Coccidioides-endemic region that acquire infection are at risk for complicated and protracted infection. Following transplantation, prophylaxis…2018 American Transplant Congress
Pneumocystis jiroveci Pneumonia (PJP) in Kidney and Pancreas Transplant Recipients in the Present Era of Routine Post-Transplant Prophylaxis: Risk Factors and Outcomes
University of Wisconsin, Madison.
PJP after transplant (TX) is associated with substantial morbidity and mortality. In the present era of universal and routine implementation of PJP prophylaxis (PPX) during…2018 American Transplant Congress
Impact of Pneumocystis Prophylaxis on Incidence of Treated Urinary Tract Infections Following Kidney Transplantation
Rush University Medical Center, Chicago, IL.
Background: Urinary tract infection (UTI) is the most common infectious complication after kidney transplantation resulting in increased morbidity and mortality. Sulfamethoxazole[mdash]trimethoprim (SMX-TMP) is commonly used…2018 American Transplant Congress
Standard- versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients
Henry Ford Hospital, Detroit, MI.
Background: Although guidelines recommend valganciclovir (VGC) 900 mg daily for cytomegalovirus (CMV) prophylaxis in solid organ transplant patients, multiple centers have reported clinical success, reduced…2018 American Transplant Congress
Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients
A. Prophylaxis has mostly replaced preemptive therapy in CMV seronegative recipients of kidneys from seropositive donors (D+/R-). Primary infections occur commonly even after six months…2018 American Transplant Congress
Outpatient Prophylactic Valganciclovir Dose Optimization Post-Renal Transplant
Purpose: Renal function rapidly changes post-transplant requiring dose adjustment of CMV prophylaxis. We describe valganciclovir (VGCV) dosing accuracy in the outpatient setting and its associated…2018 American Transplant Congress
The Incidence and Outcome of Isolated Distal Deep Vein Thrombosis in Kidney Transplant Recipient
Surgery, The Catholic University of Korea, Seoul, Republic of Korea.
Introduction Isolated distal deep vein thrombosis (IDDVT) in kidney transplantation recipient (KTR) is difficult to make decision because it is not common in Korean and…2018 American Transplant Congress
Single vs. Multi-Drug Antibiotic Prophylaxis for Continuous-Flow Left Ventricular Assist Device Implantation: A Systematic Review and Meta-Analysis
Purpose: Despite the fact that infection remains a major complication of continuous-flow left ventricular assist device (CF-LVAD) therapy, an optimal antimicrobial surgical infection prophylaxis (SIP)…2018 American Transplant Congress
Itraconazole Prophylaxis, Trough Concentration, and Identification of Fungal Pathogens in Lung Transplant
Cleveland Clinic Foundation, Cleveland, OH.
Studies of prophylactic itraconazole (ITR) in lung transplant recipients (LTR) are lacking. Our purpose was to evaluate LTR who received ITR prophylaxis and the association…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 14
- Next Page »